Compare ACRS & PSNYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRS | PSNYW |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | Sweden |
| Employees | N/A | 1686 |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.0M | 290.9M |
| IPO Year | 2015 | N/A |
| Metric | ACRS | PSNYW |
|---|---|---|
| Price | $4.54 | $3.03 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $10.20 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 5.1K |
| Earning Date | 05-07-2026 | 03-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.01 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,683,000.00 | ★ $2,034,261,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.24 | $79.49 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.22 | $0.14 |
| 52 Week High | $5.15 | $7.50 |
| Indicator | ACRS | PSNYW |
|---|---|---|
| Relative Strength Index (RSI) | 53.18 | 47.87 |
| Support Level | $4.08 | $2.88 |
| Resistance Level | $5.02 | $3.51 |
| Average True Range (ATR) | 0.26 | 0.23 |
| MACD | -0.06 | 0.04 |
| Stochastic Oscillator | 38.04 | 48.28 |
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
Polestar Automotive Holding UK PLC is a pure play, premium electric car brand, designing performance cars engineered to excite consumers and drive change. It believes that it defines market standards in design, innovation and sustainability. It is determined to improve society by accelerating the shift to sustainable mobility. The company conducts its business as one operating segment with primary commercial operations in Europe, North America, Asia Pacific and various importer markets. The company generates majority of revenue from United Kingdom.